Eikonoklastes Therapeutics is a developer of tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases. Its immunotherapies target tissue factor, a cell surface receptor that is prevalent in certain pathological cells, including a range of cancers with high unmet clinical need and high morbidity.